Evidence map›Paper›PMID 21647462›Full record

ArticleCanadian journal of gastroenterology = Journal canadien de gastroenterologie2011

Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts.

Charles Noah Bernstein, Hani El-Gabalawy, Michael Sargent, Carol Landers, Patricia Rawsthorne, Brenda Elias, Stephan R Targan

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03262649 (Manitoba Inflammatory Bowel Disease Cohort Study), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03262649 completednot on this map

Manitoba Inflammatory Bowel Disease Cohort Study

TypeobservationalSponsorUniversity of ManitobaRan2002 to 2016Enrolled388ConditionsInflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2016
    Review
  8. Article
  9. Article
  10. Epidemiology and risk factors for IBD.Nature reviews. Gastroenterology & hepatology · 2015
    Review
  11. Review
  12. Review
  13. Inflammatory bowel disease serology in Asia and the West.World journal of gastroenterology · 2013
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Charles Noah BernsteinIBD Clinical & Research Center, University of Manitoba, Wimnipeg, Manitoba. cbernst@cc.umanitoba.ca
Hani El-Gabalawy
Michael Sargent
Carol Landers
Patricia Rawsthorne
Brenda Elias
Stephan R Targan
University of Manitoba · CACedars-Sinai Medical Center · US

Funding

Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI TARGAN, STEPHAN R. · 1992 to 2020
$31.1M
CIHRNIDDK NIH HHS P01 DK046763
6 · The paper itself

Abstract

backgroundFirst Nation populations in Canada have a very low incidence of inflammatory bowel disease (IBD). Based on typical infections in this population, it is plausible that the First Nations react differently to microbial antigens with a different antibody response pattern, which may shed some light as to why they experience a low rate of IBD.

objectiveTo compare the positivity rates of antibodies known to be associated with IBD in Canadian First Nations compared with a Canadian Caucasian population.

methodsSubjects with Crohn's disease, ulcerative colitis (UC), rheumatoid arthritis (RA) (as an immune disease control) and healthy controls without a personal or family history of chronic immune diseases, were enrolled in a cohort study aimed to determine differences between First Nations and Caucasians with IBD or RA. Serum from a random sample of these subjects (n=50 for each of First Nations with RA, First Nations controls, Caucasians with RA, Caucasians with Crohn's disease, Caucasians with UC and Caucasians controls, and as many First Nations with either Crohn's disease or UC as could be enrolled) was analyzed in the laboratory for the following antibodies: perinuclear antineutrophil cytoplasmic antibody (pANCA), and four Crohn's disease-associated antibodies including anti-Saccharomyces cerevisiae, the outer membrane porin C of Escherichia coli, I2 - a fragment of bacterial DNA associated with Pseudomonas fluorescens, and the bacterial flagellin CBir-1. The rates of positive antibody responses and mean titres among positive results were compared.

resultsFor pANCA, First Nations had a positivity rate of 55% in those with UC, 32% in healthy controls and 48% in those with RA. The pANCA positivity rate was 32% among Caucasians with RA. The rates of the Crohn's disease-associated antibodies for the First Nations and Caucasians were comparable. Among First Nations, up to one in four healthy controls were positive for any one of the Crohn's disease-associated antibodies. First Nations had significantly higher pANCA titres in both the UC and RA groups than Caucasians. DISCUSSION: Although First Nation populations experience a low rate of IBD, they are relatively responsive to this particular antibody panel.

conclusionsThe positivity rates of these antibodies in First Nations, despite the low incidence of IBD in this population, suggest that these antibodies are unlikely to be of pathogenetic significance.

Indexed as

Indians, North AmericanAntibodies, Antineutrophil CytoplasmicAntibodies, FungalAntibody SpecificityArthritis, RheumatoidAutoantibodiesColitis, UlcerativeCrohn DiseaseEnzyme-Linked Immunosorbent AssayHumansImmunologic FactorsSaccharomyces cerevisiaeWhite PeopleAntibodies, Antineutrophil CytoplasmicAntibodies, FungalAutoantibodiesImmunologic Factors

Identifiers

PMID21647462
PMCPMC3115008
OpenAlexW1945289679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.